Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 16, Number 3—March 2010
Research

Serologic Markers for Detecting Malaria in Areas of Low Endemicity, Somalia, 2008

Teun BousemaComments to Author , Randa M. Youssef, Jackie Cook, Jonathan Cox, Victor A. Alegana, Jamal Amran, Abdisalan M. Noor, Robert W. Snow, and Chris J. Drakeley
Author affiliations: London School of Hygiene and Tropical Medicine, London, UK (T. Bousema, J. Cook, J. Cox, C. Drakeley); University of Alexandria, Alexandria, Egypt (R.M. Youssef); Kenya Medical Research Institute–Wellcome Trust Research Programme, Nairobi, Kenya (R.M. Youssef, V.A. Alegana, J. Amran, A.M. Noor, R.W. Snow); Roll Back Malaria–World Health Organization, Hargeisa, Somalia (J. Amran); University of Oxford, Oxford, UK (A.M. Noor, R.W. Snow)

Main Article

Figure 1

Seroprevalence data for antibodies against A) Plasmodium falciparum merozoite surface protein 119 (MSP-119), B) P. falciparum apical membrane antigen 1 (AMA-1), C) P. vivax MSP-119, and D) P. vivax AMA-1 by age in the study population, Somalia, 2008. Gray lines indicate 95% confidence intervals. Seroconversion rates (95% confidence intervals) were as follows: P. falciparum MSP-119 0.0082 (0.0068–0.097); AMA-1 0.0053 (0.0042–0.0066); P. vivax MSP-119 0.0086 (0.0055–0.0133); AMA-1 0.0075 (0.0050–0

Figure 1. Seroprevalence data for antibodies against A) Plasmodium falciparum merozoite surface protein 119 (MSP-119), B) P. falciparum apical membrane antigen 1 (AMA-1), C) P. vivax MSP-119, and D) P. vivax AMA-1 by age in the study population, Somalia, 2008. Gray lines indicate 95% confidence intervals. Seroconversion rates (95% confidence intervals) were as follows: P. falciparum MSP-119 0.0082 (0.0068–0.097); AMA-1 0.0053 (0.0042–0.0066); P. vivax MSP-119 0.0086 (0.0055–0.0133); AMA-1 0.0075 (0.0050–0.0112).

Main Article

Page created: December 14, 2010
Page updated: December 14, 2010
Page reviewed: December 14, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external